About

About SWISS Pavilion Switzerland at BIO 2025: Innovation, Collaboration, and Global Impact Welcome to the SWISS Pavilion at BIO International Convention 2025 – your gateway to one of the world’s most dynamic and resilient biotech ecosystems. Switzerland stands at the forefront of global biotechnology, driven by a unique blend of scientific excellence, international collaboration, and a deep commitment to innovation that benefits patients and partners worldwide. Switzerland’s biotech industry continues to demonstrate remarkable strength and adaptability. According to the Swiss Biotech Report 2025, the sector attracted CHF 2.5 billion in capital investment in 2024 – a 22% increase over the previous year – despite global economic headwinds. This growth reflects the confidence of international investors in Swiss innovation and the country’s ability to deliver breakthrough solutions in healthcare, diagnostics, and life sciences. With over 1,000 biotech companies and a dense network of academic institutions, research centers, and global pharma leaders, Switzerland offers a fertile environment for biotech innovation. The industry contributes significantly to the national economy, with life sciences accounting for over 50% of Swiss exports. This year’s Swiss Biotech Report emphasizes the importance of international collaboration. Four out of five biotech patents filed in Switzerland are the result of cross-border partnerships. Swiss companies are not only developing therapies for the local market – they are building global business cases, forming strategic alliances, and co-developing solutions that address some of the world’s most pressing health challenges. At the SWISS Pavilion, you’ll find a curated selection of Switzerland’s most promising biotech innovators – from agile startups and academic spin-offs to established scale-ups and research-driven SMEs. While each exhibitor brings a unique value proposition, together they represent the full spectrum of Swiss biotech excellence: - Next-generation therapeutics: From immuno-oncology to gene and cell therapies, Swiss companies are advancing novel treatment modalities with global potential. - Cutting-edge diagnostics: Precision medicine is a key focus, with technologies that enable earlier, more accurate, and personalized diagnosis. - Digital health and AI: Swiss innovators are integrating data science and machine learning into biotech workflows, accelerating discovery and improving patient outcomes. - Sustainable biomanufacturing: Several exhibitors are pioneering green biotech solutions and scalable production platforms. - Academic and regional clusters: The Pavilion also features representatives from Switzerland’s leading biotech hubs, including the Basel Area, the Greater Zurich Area, and Greater Geneva Bern area, showcasing the country’s decentralized yet interconnected innovation landscape. Why visit the SWISS Pavilion? - Meet high-potential partners: Engage with companies actively seeking international collaborations, licensing opportunities, and investment. - Explore innovation across the value chain: From early-stage research to clinical development and commercialization. - Experience Swiss quality and reliability: A hallmark of Swiss biotech is its commitment to scientific rigor, regulatory excellence, and long-term partnerships. Whether you're looking for your next strategic partner, investment opportunity, or simply want to explore the future of biotech, the SWISS Pavilion is your destination at BIO 2025. Join us in shaping the future of global health – the Swiss way. Switzerland at BIO 2026: Innovation, Collaboration, and Global Impact Welcome to the SWISS Pavilion at BIO International Convention 2026 – your gateway to one of the world’s most dynamic and resilient biotech ecosystems. Switzerland stands at the forefront of global biotechnology, driven by a unique blend of scientific excellence, international collaboration, and a deep commitment to innovation that benefits patients and partners worldwide. Switzerland’s biotech industry continues to demonstrate remarkable strength and adaptability. According to the Swiss Biotech Report 2025, the sector attracted CHF 2.5 billion in capital investment in 2024 – a 22% increase over the previous year – despite global economic headwinds. This growth reflects the confidence of international investors in Swiss innovation and the country’s ability to deliver breakthrough solutions in healthcare, diagnostics, and life sciences. With over 1,000 biotech companies and a dense network of academic institutions, research centers, and global pharma leaders, Switzerland offers a fertile environment for biotech innovation. The industry contributes significantly to the national economy, with life sciences accounting for over 50% of Swiss exports. This year’s Swiss Biotech Report emphasizes the importance of international collaboration. Four out of five biotech patents filed in Switzerland are the result of cross-border partnerships. Swiss companies are not only developing therapies for the local market – they are building global business cases, forming strategic alliances, and co-developing solutions that address some of the world’s most pressing health challenges. At the SWISS Pavilion, you’ll find a curated selection of Switzerland’s most promising biotech innovators – from agile startups and academic spin-offs to established scale-ups and research-driven SMEs. While each exhibitor brings a unique value proposition, together they represent the full spectrum of Swiss biotech excellence: - Next-generation therapeutics: From immuno-oncology to gene and cell therapies, Swiss companies are advancing novel treatment modalities with global potential. - Cutting-edge diagnostics: Precision medicine is a key focus, with technologies that enable earlier, more accurate, and personalized diagnosis. - Digital health and AI: Swiss innovators are integrating data science and machine learning into biotech workflows, accelerating discovery and improving patient outcomes. - Sustainable biomanufacturing: Several exhibitors are pioneering green biotech solutions and scalable production platforms. - Academic and regional clusters: The Pavilion also features representatives from Switzerland’s leading biotech hubs, including the Basel Area, the Greater Zurich Area, and Greater Geneva Bern area, showcasing the country’s decentralized yet interconnected innovation landscape. Why visit the SWISS Pavilion? - Meet high-potential partners: Engage with companies actively seeking international collaborations, licensing opportunities, and investment. - Explore innovation across the value chain: From early-stage research to clinical development and commercialization. - Experience Swiss quality and reliability: A hallmark of Swiss biotech is its commitment to scientific rigor, regulatory excellence, and long-term partnerships. Whether you're looking for your next strategic partner, investment opportunity, or simply want to explore the future of biotech, the SWISS Pavilion is your destination at BIO 2026. Join us in shaping the future of global health – the Swiss way. Swissenviro was founded in 2015 by Urs Heutschi. It is a small, privately-owned company and the organizer of the SWISS Pavilion at international trade fairs for environmental technologies. With more than 20 years of experience, the international fair work is our area of expertise and forms the core of our work. The aim is to support export-orientated Swiss Cleantech SME to find buyers and business partners in international markets by encouraging international networking and direct B2B contacts on trade fairs and other events. By participation in a Joint Swiss Booth, the "SWISS Pavillon", we are bringing together Swiss SMEs with professional trade visitors - potential future buyers, partners or suppliers. If desired, we gladly accompany and support the SME further on its business project resulting from this first customer contact. We closely work together with relevant Swiss environmental associations such as Cleantech Alps, VSA and Energie-Cluster. For our SWISS Pavilions we are supported by the MPK from "Switzerland Global Enterprise" (S-GE) and the "Swiss Federal Office for the Environment" (FOEN).